Antiangiogénesis Sigue siendo una alternativa? Javier de Castro Carpeño
|
|
- Theresa Roberts
- 6 years ago
- Views:
Transcription
1 Antiangiogénesis Sigue siendo una alternativa? Javier de Castro Carpeño Formigal, 24 de junio de 2016
2 Antiangiogénesis Sigue siendo una alternativa?
3 Angiogenesis: A hallmark of cancer leading to malignant growth Sustaining proliferative signaling Resisting cell death Evading growth suppressors Canc er Inducing angiogenesis Enabling replicative mortality Activating invasion and metastasis Hanahan & Weinberg. Cell 2011
4 Agents Targeting the VEGF Pathway Anti-VEGF antibodies Bevacizumab VEGF Soluble VEGFRs Aflibercept Small-molecule VEGFR TKIs Sorafenib (Bay ) Sunitinib (SU11248) Axitinib Motesanib BIBF1120 Cediranib Pazopanib Vandetanib Tivozanib Etc.. P P P P P P P P VEGFR-1 VEGFR-2 Endothelial cell Anti-VEGFR antibodies Ramucirumab Podar K, et al. Blood. 2005:105: Gori B, et al. Ther Clin Risk Manag. 2011;7:
5 CÁNCER DE PULMÓN DE CÉLULAS NO PEQUEÑAS (CPCNP) ESTADIO IV NO ESCAMOSO ESCAMOSO DETERMINAR EGFR Y ALK + - INHIBIDORES EGFR o ALK QUIMIOTERAPIA +/- bevacizumab QUIMIOTERAPIA
6 First-line induction therapy in NSCLC Overall goals of therapy Prolong OS and preserve QoL Diagnosis Treatment selection Induction Maintenance? Goals of induction Shrink the tumour and prevent early progression Control symptoms Favourable tolerability during induction allows therapy continuation
7 Phase III 1L clinical trials in nsnsclc E JMDB (non-sq) 2 Induction Carbo/pac + bev (15mg/kg) x6 Maintenance (to PD) OS from induction (months) Bev 15mg/kg 12.3 Carbo/pac x6 BSC 10.3 Cis/pem x Cis/gem x HR AVAiL 3 Cis/gem/bev (7.5/15mg/kg) x6 Bev 7.5mg/kg Bev 15mg/kg Cis/gem x6 Placebo 13.1 POINTBREAK 4 Carbo/pac+bev x4 Bev 15 mg/kg Carbo/pem+bev x4 Bev 15mg/kg+pem 12.6 PRONOUNCE 5 Carbo/pac+bev x4 Bev 15 mg/kg 11.7 Carbo/pemx4 Pem Sandler, et al. N Engl J Med Scagliotti, et al. Oncologist 2009; 3. Reck, et al. Ann Oncol 2010; 4.Patel IASLC 2012; 5. Zinner ASCO 2013
8 OS estimate E4599: 14-month OS in patients with adenocarcinoma histology E4599 adenocarcinoma population 1.0 Pac + Carbo + Bev Bev Pac + Carbo 0.8 HR=0.69 ( ) Histology n Median OS (months) HR 0.6 Non-squamous Adenocarcinoma Time (months) Bev = bevacizumab; Carbo = carboplatin; Pac = paclitaxel Sandler, et al. J Thorac Oncol 2010
9
10 OS estimate POINTBREAK: OS (primary endpoint) ITT population HR (95% CI) Pem + Carbo + Bev Pem + Bev (n=472) Pac + Carbo + Bev Bev (n=467) 1.00 ( ) p value Median OS (months) Time (months) Patel, et al. J Clin Oncol 2013
11 OS estimate AVAPERL: OS from randomisation* Bev Bev+pem NR (34 events) 15.7 months (42 events) HR=0.75 ( ); p= Cont. maintenance bev+pem (n=128) Cont. maintenance bev (n=125) Patients at risk Bev+pem Bev Time (months) *Randomised patients, Intent-to-treat population Median follow-up time: 11 months (8 months, excluding induction) 30% of events at the time of analysis Barlesi, for overall et al. JCO survival 2013
12
13 CÁNCER DE PULMÓN DE CÉLULAS NO PEQUEÑAS (CPCNP) ESTADIO IV NO ESCAMOSO ESCAMOSO TTO 2ª L TTO 2ª L PEMETREXED DOCETAXEL ERLOTINIB DOCETAXEL NIVOLUMAB NIVOLUMAB DOCETAXEL+ NINTEDANIB DOCETAXEL + RAMUCIRUMAB
14 Ramucirumab (IMC-1121B) Ramucirumab is a fully human IgG1 monoclonal antibody that binds with high affinity to human VEGFR-2 (Kd ~ 50 pm) 1 Ramucirumab is specific for the human VEGFR-2 receptor 2 Ramucirumab potently blocks binding of VEGF-A to VEGFR-2 (IC 50 = 0.8 nm) 1 Ramucirumab blocks binding of VEGF- C and VEGF-D to VEGFR Lu et al. J Biol Chem 2003;278(44): Data on file, ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company. 3. Data on file, ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company.
15 Revel Study
16 OVERALL SURVIVAL (ITT) Revel Study
17 Revel Study OVERALL SURVIVAL (SUBGROUP ANALYSIS)
18 Revel Study OVERALL SURVIVAL BY HISTOLOGY (ITT)
19 Revel Study PROGRESSION-FREE SURVIVAL
20 Revel Study RESPONSE RATES (RECIST 1.1)
21 Revel Study RESPONSE RATES (HISTOLOGY SUBTYPES)
22 Revel Study HEMATOLOGICAL ADVERSE EVENTS
23 Revel Study ADVERSE EVENTS (ANTIANGIOGENIC THERAPY)
24 Revel Study QUALITY OF LIFE (LCSS, ASBI)
25 Nintedanib Nintedanib, a triple angiokinase inhibitor Mode of action By targeting the 3 major angiogenesis signaling pathways Nintedanib prevents further tumor growth and related tumor escape mechanisms Ligands VEGFs Stimulation Cell type/receptors Endothelial cells VEGFRs, FGFRs FGFs Pericytes PDGFRs PDGFs Smooth muscle cells FGFRs, PDGFRs a Angiokinase refers to tyrosine receptor kinases involved in promoting angiogenesis. Hilberg F et al. Cancer Res 2008; 68: (12). June 15, 2008] 25 VEGF: vascular endothelial growth factor FGF: fibroblast growth factor PDGF: platelet -derived growth factor
26 LUME-Lung 1: study design Stage IIIB/IV or recurrent NSCLC patients after first-line chemotherapy (all histologies) R A N D O M IZ E 1:1 BIBF mg BID p.o., Day Docetaxel 75 mg/m 2 IV, Day 1, 21-day cycles (n=655) Placebo BID p.o., Day Docetaxel 75 mg/m 2 IV, Day 1, 21-day cycles (n=659) PD PD n=1314 Number of docetaxel cycles not restricted Monotherapy allowed after 4 cycles of combination therapy Stratification: ECOG PS (0 vs. 1) Prior bevacizumab (yes vs. no) Histology (squamous vs. non-squamous) Brain metastases (yes vs. no) Regions: Europe/Asia/South Africa Accrual: 23 Dec 2008 to 09 Feb 2011 Reck M, et al. Lancet Oncol 2014; 15:
27 Probability of PFS (%) LUME-Lung 1: primary endpoint met significantly longer PFS with the addition of nintedanib to docetaxel Nintedanib + docetaxel Placebo + docetaxel Median PFS (months) HR = 0.79 (95% CI: ); p= Time (months) No. at risk Nintedanib Placebo Reck M, et al. Lancet Oncol 2014;15: Independent central review in all patients
28 Probability of survival (%) OS: Key secondary endpoint All patients Nintedanib + docetaxel Placebo + docetaxel Median, mo HR (95% CI) 0.94 ( ) p value Number at risk Nintedanib Placebo Time (months) OS = overall survival; mo = months; HR = hazard ratio; CI = confidence interval. Reck M, et al. Lancet Oncol. 2014;15:
29 Probability of survival (%) OS: Key secondary endpoint met Patients with adenocarcinoma histology % Nintedanib + docetaxel Placebo + docetaxel Median, mo HR (95% CI) 0.83 ( ) p value % 25.7% Number at risk Nintedanib Placebo % Time (months) OS = overall survival; mo = months; HR = hazard ratio; CI = confidence interval. Reck M, et al. Lancet Oncol. 2014;15:
30 Best tumor response Independent Central Review in Major Histologies Adenocarcinoma Squamous Cell Carcinoma Best response, n (%) Nintedanib + docetaxel (n=322) Placebo + docetaxel (n=336) Nintedanib + docetaxel (n=276) Placebo + docetaxel (n=279) Complete response (CR) (0.4) Partial response (PR) 15 (4.7) 12 (3.6) 13 (4.7) 6 (2.2) Stable disease (SD) 179 (55.6) 136 (40.5) 123 (44.6) 92 (33.0) Disease control rate* (CR + PR + SD) 194 (60.2) 148 (44.0) 136 (49.3) 99 (35.5) Progressive disease 87 (27.0) 147 (43.8) 90 (32.6) 134 (48.0) *Statistically significant improvement in disease control rate with nintedanib + docetaxel (Odds ratio 1.93; p< for adenocarcinoma and Odds ratio 1.78, p< for squamous cell carcinoma)
31 Key secondary endpoint Primary endpoint LUME-Lung 1: hierarchical analysis used to reduce error rate and maintain power for the important OS endpoint Independently assessed PFS All histologies Previously analysed trial, LUME-Lung 2, showed enhanced benefit in early progressing adenocarcinoma tumours, so stepwise testing was used to preserve power and reduce error* Significant finding for PFS at time of OS OS Adenocarcinoma Time since start of first-line therapy <9 months Significant finding OS All adenocarcinoma Significant finding OS All histologies *Hanna N, et al. ASCO Abstract #8034; Hanna N, et al. ESMO Abstract #3418; Kaiser R, et al. ESMO Abstract #3479. Reck M, et al. Lancet Oncol 2014;15:
32 Probability of survival (%) OS: Key secondary endpoint met Adenocarcinoma + time since start of first-line therapy <9 months Nintedanib + docetaxel Placebo + docetaxel Median, mo % HR (95% CI) 0.75 (0.60 to 0.92) p value Feb 2013, 345 events % 17.0% Number at risk Nintedanib Placebo 0 8.5% Time (months) OS = overall survival; mo = months; HR = hazard ratio; CI = confidence interval. Reck M, et al. Lancet Oncol. 2014;15:
33 Adverse Events Occurring in 5% of the Patients With Adenocarcinoma Nintedanib + docetaxel (n=320) n (%) Placebo + docetaxel (n=333) n (%) All grades Grade 3 All grades Grade 3 Any AE 308 (96.3) 243 (75.9) 314 (94.3) 228 (68.5) Diarrhoea 139 (43.4) 20 (6.3) 82 (24.6) 12 (3.6) Neutrophil count decreased 131 (40.9) 116 (36.3) 135 (40.5) 116 (34.8) ALT increased 121 (37.8) 37 (11.6) 31 (9.3) 3 (0.9) Fatigue 99 (30.9) 15 (4.7) 98 (29.4) 14 (4.2) AST increased 97 (30.3) 13 (4.1) 24 (7.2) 2 (0.6) Nausea 91 (28.4) 3 (0.9) 59 (17.7) 2 (0.6) White blood cell count decreased 89 (27.8) 63 (19.7) 94 (28.2) 61 (18.3) Decreased appetite 75 (23.4) 4 (1.3) 52 (15.6) 5 (1.5) Vomiting 62 (19.4) 4 (1.3) 41 (12.3) 2 (0.6) Alopecia 56 (17.5) 1 (0.3) 68 (20.4) 0 (0) Dyspnoea 54 (16.9) 15 (4.7) 52 (15.6) 20 (6.0) Neutropenia 44 (13.8) 38 (11.9) 51 (15.3) 45 (13.5) Only 1.2% of the patients in the nintedanib arm discontinued treatment due to diarrhoea Cough 42 (13.1) 3 (0.9) 63 (18.9) 2 (0.6) Pyrexia 39 (12.2) 2 (0.6) 47 (14.1) 1 (0.3) 1.7% of the patients treated with nintedanib discontinued due to liver-related investigations Stomatitis 36 (11.3) 4 (1.3) 26 (7.8) 1 (0.3) Haemoglobin decreased 35 (10.9) 3 (0.9) 46 (13.8) 7 (2.1) Constipation 22 (6.9) 0 (0) 39 (11.7) 1 (0.3) LUME-Lung 1 Adverse events were classified according to Common Terminology Criteria for Adverse Events version 3.0 Reck et al. Lancet Oncol. 2014;15: Suppl.
34 Early vs Late Progressors: Mechanistic Hypothesis Rapidly progressing adenocarcinomas depend more strongly on vascularization for oxygen and nutrient supply than slowly growing tumors High intrinsic rate of tumor cell proliferation (oncogenome-dependent) Rapid disease progression High-level production of angiogenic growth factors by tumor cells High-level angiogenesis nintedanib
35 Probability of survival (%) Consistent Trend Towards Survival Benefit Regardless of Prior Treatment in Patients With Adenocarcinoma Overall Survival by Prior First-line Chemotherapy Prior taxane treatment Nintedanib + docetaxel Placebo + docetaxel Median OS (months) HR = 0.75 (95% CI: ) Prior pemetrexed treatment Nintedanib + docetaxel Placebo + docetaxel Median OS (months) HR = 0.79 (95% CI: ) Prior bevacizumab treatment Nintedanib + docetaxel Placebo + docetaxel Median OS (months) HR = 0.61 (95% CI: ) Time (months) Time (months) Time (months) No. at risk Nintedanib Placebo CI = confidence interval; HR = hazard ratio; OS = overall survival. Krzakowski M, et al. Ann Oncol (2014);25(Suppl 4): iv158. Abstract 471P and poster; Mellemgaard A, et al. Ann Oncol (2014);25(Suppl 4): iv157. Abstract 473P and poster; Boehringer Ingelheim data on file.
36 OS (%) OS (%) OS by PD-L1 Expression 100 1% PD-L1 expression level 100 5% PD-L1 expression level % PD-L1 expression level mos (mo) Nivo 17.2 Doc Niv o mos (mo) 18.2 Doc Niv o mos (mo) 19.4 Doc Nivo Doc HR (95% CI) = 0.59 (0.43, 0.82) 10 HR (95% CI) = 0.43 (0.30, 0.63) 10 HR (95% CI) = 0.40 (0.26, 0.59) Time (months) Time (months) Time (months) <1% PD-L1 expression level 90 <5% PD-L1 expression level 90 <10% PD-L1 expression level mos (mo) Nivo mos (mo) Nivo mos (mo) Nivo Nivo Doc Doc Doc Doc HR (95% CI) = 0.90 (0.66, 1.24) 10 HR (95% CI) = 1.01 (0.77, 1.34) 10 HR (95% CI) = 1.00 (0.76, 1.31) Time (months) Time (months) Time (months) Symbols represent censored observations.
37 SELECCIÓN DE PACIENTES CUESTIONES PENDIENTES DESARROLLO DE RESISTENCIA INMUNOTERAPIA
38 PFS Estimate OS Estimate AVALON: bevacizumab long survivals Progression Free Survival Overall Survival Median PFS: 15 m (95% CI:14-16) Median OS: 31 m (95% CI: 22-39) 1-yr survival: 97% (95% CI: ) 2-yr survival: 62% (95% CI: 51-73) Months Months Most frequent toxicities Response Rate AE (% of patients) Grade 1 Grade 2 Grade 3 Grade 4 Epistaxis Hypertension Asthenia Proteinuria n % 95% CI Objective Response Rate 86 83% (74-89) Complete Response (CR) 9 9% Partial Response (PR) 77 74% Stable disease (SD) 18 17% De Castro et al, Clin Transl Oncol 2016
39 AvaALL Beyond the horizon... beyond progression Stage IIIB/IV non-squamous NSCLC treated with platinumdoublet (4 6 cycles) + bevacizumab PLUS >2 cycles of bevacizumab Maintenance (n=600) Enroll Phase IIIb study of bevacizumab continued beyond progression Primary endpoint: OS PD 1 Secondary endpoints include PFS, safety, QoL and biomarker analysis Actively recruiting patients R A N D O M I S E 1:1 Primary endpoint: OS SOC2 * + bevacizumab PD 2 SOC3 + bevacizumab PD 3 SOC4 ± bevacizumab SOC2* SOC3 SOC4 *SOC2: labelled agents for second-line treatment of NSCLC SOC3 and beyond: choice of labelled agents is the investigator s choice Gridelli, et al. Clin Lung Cancer 2011
40 Jinushi M et al, Clin Cancer Res 2007
41 Limitations of Anti-Angiogenic Therapies Moserle, Jiménez-Valerio & Casanovas Cancer Discovery, 2014
42 Anti-T antigen H&E Tumor Adaptation to Antiangiogenics: more Invasion and Metastasis Control (end-stage) Anti-VEGFR2 1 week Anti-VEGFR2 4 weeks 150 µm 150 µm 150 µm Ac Ac Ac T 50 µm T 50 µm 50 µm T Pàez-Ribes et al. Cancer Cell 2009
43 How to Block Alternative Proangiogenic Resistance? Biological base of combining anti-vegfr and Immunotherapy? Inhibition of VEGF-VEGFR exerts some Immune Activation! Vanneman & Dranoff Nat.Rev.Cancer 2012
44 Factors controlling infiltration of T cells into solid tumors CY Slaney Cancer Res; 74(24);
45 CÁNCER DE PULMÓN DE CÉLULAS NO PEQUEÑAS (CPCNP) ESTADIO IV NO ESCAMOSO ESCAMOSO DETERMINAR EGFR Y ALK + - INHIBIDORES EGFR o ALK QUIMIOTERAPIA +/- bevacizumab QUIMIOTERAPIA
46 Erlotinib + Bevacizumab JO25567 phase II study of 1L erlotinib ± bevacizumab in Japanese patients with EGFR Mut+ NSCLC Stage IIIB/IV or recurrent NSCLC Non-squamous histology EGFR Mut+ exon 19 deletion / L858R* No prior treatment ECOG PS 0 1 (n=152) R Bevacizumab 15mg/kg i.v. q3w + erlotinib 150mg/day 1:1 Stratified by: gender, stage, smoking status, EGFR Mut type Erlotinib 150mg/day PD PD Primary endpoint PFS by independent review Secondary endpoints QoL OS Safety ORR DCR Response duration *T790M excluded; EGFR mutation assays performed at investigational site using: PNA LNA PCR Clamp PCR-Invader, Cycleave or Other methods ECOG PS = Eastern Cooperative Oncology Group performance status; DCR = disease control rate i.v. = intravenous; ORR = overall response rate; PD = progressive disease QoL = quality of life; q3w = every 3 weeks Exploratory endpoints Biomarkers JapicCTI Seto, et al. Lancet Oncol 2014
47 Tumour volume change from baseline (%) Tumour volume change from baseline (%) JO25567: tumour response Bevacizumab + erlotinib Responder (CR or PR) Non-responder (SD, PD or NE) Erlotinib CR = complete response; NE = non-evaluable; PR = partial response; SD = stable disease Seto, et al. Lancet Oncol 2014
48 PFS probability JO25567: PFS by independent review in all patients (primary endpoint) Bevacizumab + erlotinib (n=75) Erlotinib (n=77) HR=0.54 ( ) Log-rank p= months Time (months) Seto, et al. Lancet Oncol 2014
49 PFS estimate PFS estimate Kato, et al. ASCO 2014 JO25567 (1L erlotinib + bevacizumab vs 1L erlotinib): PFS by EGFR mutation type Exon 19 deletion Erlotinib + bevacizumab: 18.0 months Erlotinib: 10.3 months HR=0.41 ( ) Exon 21 L858R Erlotinib + bevacizumab: 13.9 months Erlotinib: 7.1 months HR=0.67 ( ) Time (months) Time (months)
50 Other phase II studies of an EGFR TKI + bevacizumab in 1L treatment of EGFR Mut+ NSCLC RC ACCRU [USA] Primary endpoint: PFS Stage IV NSCLC Non-squamous histology ECOG PS 0 1 (n=150) R Erlotinib 150mg/day Erlotinib 150mg/day + bevacizumab 15mg/kg i.v. q3w BELIEF 2 ETOP [EU] Primary endpoint: PFS Stage IIIB/IV NSCLC Non-squamous histology ECOG PS 0 2 (n=102) Erlotinib 150mg/day + bevacizumab 15mg/kg i.v. q3w Sub-study 1: T790M+ (n=35) Sub-study 2: T790M (n=67) OLCSG OLCSG [JAPAN ] Stage IV NSCLC Non-squamous histology ECOG PS 0 2 (n=42) Primary endpoint: 1-yr PFS rate Gefitinib 250mg/day + bevacizumab 15mg/kg i.v. q3w 1. NCT ; 2. NCT ; 3. Nogami, et al. ESMO 2014
51 ETOP 2-11 BELIEF: PFS by T790M mutation (N=109) Events/N Median PFS (95%CI) 12m PFS (95%CI) All 57/ m ( ) 56.7% ( ) T790M+ 15/ m (13.1-NE) 72.4% ( ) T790M- 42/ m ( ) 49.4% ( ) ETOP 2-11 BELIEF 18 th ECCO 40 th ESMO European Cancer Congress, September 2015
52 ETOP 2-11 BELIEF 18 th ECCO 40 th ESMO European Cancer Congress, September 2015 ETOP 2-11 BELIEF: PFS by Exon19/21 (N=109) Events/N Median PFS (95%CI) All 57/ m ( ) Exon19+ 35/ m ( ) Exon21+ 22/ m ( ) Med PFS T790M m T790M m Exon19+ pts Med PFS T790M m T790M- 9.4 m Exon21+ pts
53 Potential to prevent or delay resistance: T790M Preclinical data Data suggest erlotinib + bevacizumab is active against T790M+ tumours EGFR L858R T790M Bev = 68% inhibition Bev + erlotinib = 75% inhibition Naumov, et al. Clin Cancer Res 2009
54 TRATAMIENTO EFICAZ COMPLEMENTARIO Y NO EXCLUYENTE Antiangiogénicos en Ca de Pulmón BÚSQUEDA DE PACIENTES CANDIDATOS NO RESISTENCIA CRUZADA ENTRE ANTIANGIOGÉNICOS
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationVEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationSecond-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationThe Story of BIBF1120 Nintedanib Vargatef. To be told by Rolf Kaiser & Claudia-Nanette Gann
1 The Story of BIBF1120 Nintedanib Vargatef To be told by Rolf Kaiser & Claudia-Nanette Gann The Story Started in 1971 2 Folkman J. New Eng J Med 1971;285:1182 1186. What Role Does Angiogenesis Play in
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationNintedanib in Oncology Backgrounder
For media outside the US, UK and Canada only Nintedanib in Oncology Backgrounder 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. Additional clinical data 5. Nintedanib approval
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationSao Paulo, Abril 2014
Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationMaintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More information1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC)
1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC) Role of the VEGF Pathway in Oncogenesis The Role of Angiogenesis in Cancer Somatic mutation Small avascular tumor Tumor secretion of
More informationTreatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
More informationTargeted Therapies in Melanoma
Mutations and Targets Targeted Therapies in Melanoma ckit NRAS
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationin combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
More informationCarcinoma de Tiroide: Teràpies Diana
Carcinoma de Tiroide: Teràpies Diana Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology THYROID CANCER:
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationNew Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management
New Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management Ramaswamy Govindan, MD Director Professor of Medicine Director, Thoracic Oncology Program Department
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationThe Role of Angiogenesis Inhibition in Breast Cancer Today: Lessons Learned
The Role of Angiogenesis Inhibition in Breast Cancer Today: Lessons Learned Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education UCSF Helen Diller Family Comprehensive
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationCooperative Group Update - Japan; JCOG & WJOG -
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine, Yokohama City University Chief, Division of Thoracic Surgery, Respiratory Disease Center
More informationComparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
J Lung Cancer 2009;8(2):61-66 Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC) More effective treatments in first, second, and third-line of metastatic
More informationTratamiento de la enfermedad avanzada en cáncer de pulmón
Tratamiento de la enfermedad avanzada en cáncer de pulmón S. Ponce Aix! S. Oncología Médica Hospital Universitario 12 de Octubre Madrid Survival by stage NSCLC Stage Distribution NSCLC Stage 5-year Survival
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationBackground 1. Comparative effectiveness of nintedanib
NCPE report on the cost effectiveness of nintedanib (Vargatef ) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationMaintenance Treatment of Advanced NSCLC
Maintenance Treatment of Advanced NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it UNIVERSTY OF TORINO DEPT. OF OF Maintenance /Consolidation/Sequencing
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationAngiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)
Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC) Richard D. Hall 1, Tri
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationHacia una mayor individualización clínica en el CPNM. J.M. Sánchez Torres H.U. Princesa, Madrid
Hacia una mayor individualización clínica en el CPNM J.M. Sánchez Torres H.U. Princesa, Madrid Lung cancer histologic subtypes NSCLC (80-85%) SCLC (15-20%) Squamous carcinoma (25 30%) Non-squamous carcinoma
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer April 1, 2016
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer April 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More information